Zuckerberg San Francisco General Hospital (ZSFG) is our community’s medical center: a key part of the San Francisco Health Network, providing over half a million outpatient visits, including specialty care, and service to over 100,000 inpatients. ZSFG is San Francisco’s primary safety-net provider, serving a high number of economically disadvantaged residents.

ZSFG operates the only Level 1 trauma center for San Francisco and northern San Mateo County. Being cared for at ZSFG lowers the risk of death by 20 – 25% compared to non-trauma centers.

ZSFG also maintains the only Psychiatric Emergency Service in San Francisco, with nearly 7,000 annual encounters.

Eighteen affiliated Safety Net clinics also participate in 340B.

The 340B prescription drug program is a vital lifeline for safety-net providers, supporting critical health services in our communities. The program is narrowly tailored to reach only hospitals that provide a high level of services to low-income individuals or that serve isolated rural communities. Savings from the 340B program help hospitals meet the healthcare needs of underserved patients across the country.

Congress should preserve and protect the 340B program as an essential part of the safety-net that does not rely on taxpayer dollars.

Our 340B savings enable us to provide critical services to our community. Without 340B, these services are at risk:

- Discharge Pharmacy that is essential to reducing hospital readmission rates
- Free medications to un-insured
- Dedicated pharmacy staff that assist patients who need help paying for expensive medications
- Specialized support for persons with HIV and hepatitis C

### 340B by the Numbers

- **$154.5 M** Uncompensated care provided last year.
- **$1.6 M** Medications provided last year to patients who could not otherwise afford to pay.
- **$10 M** Approximate annual 340B drug cost savings.
- **- $0.5 M** Decrease in hospital revenue from Medicare B change.
- **$40.7 M** Charity Care
- **- $7.4 M** Increase in drug costs from State budget proposal.

Congress created 340B in 1992. 340B costs taxpayers nothing. 340B sales are less than 3% of the $457 billion U.S. drug market.

Source: AAMC.org/340B